KineMed Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KineMed Inc.
Execs On The Move, July-August 2014
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Medtech Execs On The Move, June-July 2014
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Nascent Sarcopenia Pipeline’s First Target Is Myostatin
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.
Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice